LONDON Jan 22 AstraZeneca said European
regulators had approved Xigduo for type 2 diabetes, in what was
the first green light for a fixed dose combination of a SGLT2
inhibitor and metformin.
The drug combines in a twice daily tablet Forxiga, a SGLT2
inhibitor that reduces the reabsorption of excess glucose, and
metformin, a standard in treating the condition.
Xigduo was developed by the alliance in diabetes therapy
between the British company and Bristol-Myers Squibb,
the companies said on Wednesday. AstraZeneca will take full
control of the unit later this quarter.